How to take Ramucirumab
The common pharmaceutical specifications of Ramucirumab are injection preparations, which should be administered under the supervision and guidance of a professional doctor or nurse. Before each infusion of the drug, all patients must be pre-intravenously infused with a histamine-1 receptor antagonist (such as diphenhydramine hydrochloride). If the first infusion is tolerated, all subsequent Ramucirumab infusions can be performed within 30 minutes and used until disease progression or unacceptable toxicity occurs.
The recommended dose for the treatment of adenocarcinoma of the stomach or gastroesophageal junction is 8 mg/kg every 2 weeks as an intravenous infusion over 60 minutes, alone or in combination with weekly paclitaxel. When coadministered with paclitaxel, administer ramucirumab before paclitaxel. The recommended dose for the treatment of non-small cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations is 10 mg/kg every 2 weeks during or after platinum-based chemotherapy, as an intravenous infusion over 60 minutes on Day 1 of a 21-day cycle before docetaxel infusion. The recommended dose for the treatment of colorectal cancer is 8 mg/kg every 2 weeks, administered by intravenous infusion 60 minutes before the dose of FOLFIRI. The recommended dose in the treatment of hepatocellular carcinoma is 8 mg/kg every 2 weeks.
The original drug of ramucizumab has been launched in China, but it has been on the market for a short time and has not been included in the medical insurance. The price of 100mg/10mL box may be around 5,000 yuan, and the price of 500mg/50mL box may be around 17,000 yuan. The price of the original Hong Kong version of 100mg/10mL may be around RMB 8,400 per box, and the price of 500mg/50mL per box may be around RMB 28,000 (the price may fluctuate due to exchange rates), and their pharmaceutical ingredients are basically the same. Currently, there are no generic drugs produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)